Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Cellular Biochemistry|June 7, 2007
Tip60 modulates PLAGL2-mediated transactivation by acetylationJinying Ning, Gang Zheng, Yu-Chung Yang
Biochemical and Biophysical Research Communications|October 24, 2007
PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53Gang Zheng, Jinying Ning, Yu-Chung Yang
Journal of Cancer Research and Clinical Oncology|May 11, 2004
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancerLirong Peng, Jinying Ning, Ling Meng, et al.
Plos One|August 22, 2024
Neutralizing antibody against GDF15 for treatment of cancer-associated cachexiaJunyi Xiong, Guojin Wu, Jinying Ning, et al.
Plos One|May 10, 2013
HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cellsRong Guo, Yong Li, Jinying Ning, et al.
International Journal of Cancer|February 19, 2016
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitorsMengmeng Yang, Xiaoxi Xu, Jie Cai, et al.
ACS Chemical Biology|September 16, 2024
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96Randa Mahran, Jonas N Kapp, Salla Valtonen, et al.
Frontiers in Bioscience : a Journal and Virtual Library|December 1, 2004
AKT/PKB signaling mechanisms in cancer and chemoresistanceDonghwa Kim, Han C Dan, Sungman Park, et al.
Molecular Pharmacology|August 18, 2012
Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirsWenchang Guo, Ruiwu Liu, Yoko Ono, et al.
Scientific Reports|April 19, 2024
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical modelsTao Yang, Hang Ke, Jinping Liu, et al.
Pageof 1